Vitae Biomedical Co., Ltd. presented its non-invasive urine-based lung cancer detection technology at INNOZONE during the Taiwan Healthcare+ Expo, one of Asia’s leading platforms for healthcare innovation.

Selected as a National Innovation Award recipient, the company showcased its diagnostic platform within a curated innovation zone, highlighting its proprietary approach to early cancer detection. The technology, characterized by non-invasive sampling and operational simplicity, has already established a foundation through multi-region patent protection.

During the event, Dr. Li Yi-Shu, CEO of Vitae Biomedical, delivered a presentation on the company’s latest progress in early lung cancer detection platforms. The session drew strong interest from distributors, healthcare providers, and diagnostic laboratories, reflecting growing demand for accessible, efficient, and patient-friendly screening solutions.

The exhibition also served as a platform for expanding international engagement. Potential partners from the United States and Thailand expressed interest in collaboration, while discussions with Japanese distributors continued to build on previous exchanges initiated at the Taipei Forum in Osaka. These interactions indicate ongoing momentum toward international market development.

Domestically, the company explored collaboration opportunities with healthcare and technology partners, including applications in AI-driven imaging, health data integration, and post-diagnostic care. Such cross-disciplinary engagement supports the broader goal of enhancing diagnostic accuracy and expanding the value of non-invasive screening solutions.

Through participation in INNOZONE, Vitae Biomedical continues to strengthen its presence within the global healthcare innovation ecosystem, reinforcing both its technological credibility and its readiness for international collaboration.